<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00883870</url>
  </required_header>
  <id_info>
    <org_study_id>SRPL/CLI/07-08/001</org_study_id>
    <nct_id>NCT00883870</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells in Critical Limb Ischemia</brief_title>
  <official_title>A Randomized, Double Blind, Multicentric, Placebo Controlled, Single Dose, Phase - i/ii Study Assessing the Safety and Efficacy of Intramuscular ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With Critical Limb Ischemia (Cli)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stempeutics Research Pvt Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stempeutics Research Pvt Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial aims to study the safety and efficacy of adult mesenchymal stem cells in
      critical limb ischemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AE and symptomatic relief</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in transcutaneous partial oxygen pressure (TcPO2) and Ankle brachial pressure index (ABPI) - measured by Doppler</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mesenchymal stem cells</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>mesenchymal stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plasmalyte A</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females with non-child bearing potential in the age group of 18-60 yrs of
             Indian origin.

          -  Established CLI, clinically and hemodynamically confirmed as per Rutherford- II-4,
             III-5, or III-6; Patients having Infra-inguinal arterial occlusive disease with rest
             pain or ischemic ulcer/necrosis, who are not eligible for or have failed traditional
             revascularization treatment (No option patients)

          -  Ankle Brachial Pressure Index (ABPI) ≤ 0.6 or ankle pressure ≤ 70 mm Hg or TcPO2 ≤ 60
             mmHg in the foot

          -  Patients if having associated Type II Diabetes, should be on medication and well
             controlled (HbA1c ≤ 8%) without complications

          -  Patients who are able to understand the requirements of the study, and willing to
             provide voluntary written informed consent, abide by the study requirements, and agree
             to return for required follow-up visits

          -  Normal liver and renal function

          -  On regular medication for hypertension if any

        Exclusion Criteria:

          -  Patients with CLI suitable for surgical or percutaneous revascularization as
             determined by the surgeon performing vascular procedure and patients with any
             acute/chronic inflammatory condition

          -  CLI patient requiring amputation proximal to trans-metatarsal level

          -  Patients with gait disturbance for reasons other than CLI.

          -  Type I diabetes

          -  Patients having respiratory complications/left ventricular ejection fraction &lt; 25%f)
             Stroke or myocardial infarction within last 3 months

          -  Patients who are contraindicated for MRA

          -  Have clinically serious and/or unstable inter-current infection, medical illnesses or
             conditions that are uncontrolled or whose control, in the opinion of the Investigator,
             may be jeopardized by participation in this study or by the complications of this
             therapy

          -  Documented terminal illness or cancer or any concomitant disease process with a life
             expectancy of less than 1 year

          -  Patients already enrolled in another investigational drug trial or completed within 3
             months.

          -  History of severe alcohol or drug abuse within 3 months of screening.

          -  Hb% &lt; 10 gm%, Serum Creatinine ≥ 2mg%, Serum Total Bilirubin ≥2mg%, HbA1c &gt; 8%

          -  Women with child bearing potential, pregnant and lactating women.

          -  Patients tested positive for HIV 1, HCV, HBV,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suresh K R</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bhagawan Mahaveer Jain Heart Centre, Bangalore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sanjay Desai</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.S.Ramaiah Memorial Hospital, Bangalore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajiv Parakh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sri Ganga Ram Hospital, New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sudhindran S</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amrita Institute of Medical Sciences, Kochi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M.S.Ramaiah Memorial Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhagawan Mahaveer Jain Heart Centre</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>5660052</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amrita Institute of Medical Sciences</name>
      <address>
        <city>Kochi</city>
        <state>Kerala</state>
        <zip>682026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sri Ganga Ram Hospital</name>
      <address>
        <city>New Delhi</city>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2009</study_first_submitted>
  <study_first_submitted_qc>April 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2009</study_first_posted>
  <last_update_submitted>March 4, 2013</last_update_submitted>
  <last_update_submitted_qc>March 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mesenchymal stem cells</keyword>
  <keyword>critical limb ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasma-lyte 148</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

